JP2017513906A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513906A5 JP2017513906A5 JP2016564193A JP2016564193A JP2017513906A5 JP 2017513906 A5 JP2017513906 A5 JP 2017513906A5 JP 2016564193 A JP2016564193 A JP 2016564193A JP 2016564193 A JP2016564193 A JP 2016564193A JP 2017513906 A5 JP2017513906 A5 JP 2017513906A5
- Authority
- JP
- Japan
- Prior art keywords
- lactobacillus
- bifidobacterium
- composition
- composition according
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 18
- 241000186000 Bifidobacterium Species 0.000 claims 8
- 241000186660 Lactobacillus Species 0.000 claims 7
- 229940039696 lactobacillus Drugs 0.000 claims 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 6
- 229920002674 hyaluronan Polymers 0.000 claims 6
- 229960003160 hyaluronic acid Drugs 0.000 claims 6
- 239000006041 probiotic Substances 0.000 claims 5
- 235000018291 probiotics Nutrition 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 230000000529 probiotic effect Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 244000199866 Lactobacillus casei Species 0.000 claims 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims 2
- 229940017800 lactobacillus casei Drugs 0.000 claims 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 241000193815 Atopobium minutum Species 0.000 claims 1
- 241000186012 Bifidobacterium breve Species 0.000 claims 1
- 241001608472 Bifidobacterium longum Species 0.000 claims 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 241001430190 Eggerthia catenaformis Species 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 240000001046 Lactobacillus acidophilus Species 0.000 claims 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims 1
- 240000001929 Lactobacillus brevis Species 0.000 claims 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims 1
- 241000186679 Lactobacillus buchneri Species 0.000 claims 1
- 241000186605 Lactobacillus paracasei Species 0.000 claims 1
- 240000006024 Lactobacillus plantarum Species 0.000 claims 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims 1
- 241000186604 Lactobacillus reuteri Species 0.000 claims 1
- 241001438705 Lactobacillus rogosae Species 0.000 claims 1
- 241000194037 Lactococcus raffinolactis Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 241000194020 Streptococcus thermophilus Species 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229940009291 bifidobacterium longum Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims 1
- 229940072205 lactobacillus plantarum Drugs 0.000 claims 1
- 229940001882 lactobacillus reuteri Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
- 229960004963 mesalazine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- -1 pomade Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2014A000751 | 2014-04-23 | ||
| ITMI20140751 | 2014-04-23 | ||
| PCT/IB2015/052938 WO2015162570A1 (en) | 2014-04-23 | 2015-04-22 | Topical composition for use in the treatment of inflammatory bowel disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017513906A JP2017513906A (ja) | 2017-06-01 |
| JP2017513906A5 true JP2017513906A5 (cg-RX-API-DMAC10.html) | 2018-06-07 |
Family
ID=50981755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564193A Pending JP2017513906A (ja) | 2014-04-23 | 2015-04-22 | 炎症性腸疾患の治療に使用するための局所用組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11464814B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3134072A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2017513906A (cg-RX-API-DMAC10.html) |
| CA (1) | CA2944118C (cg-RX-API-DMAC10.html) |
| MA (1) | MA39710A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2015162570A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20131467A1 (it) | 2013-09-06 | 2015-03-07 | Sofar Spa | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
| MA39710A (fr) | 2014-04-23 | 2015-10-29 | Sofar Spa | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
| IT201600083376A1 (it) | 2016-08-08 | 2018-02-08 | Sofar Spa | Uso di probiotici per aumentare l’assorbimento proteico |
| ITUA20164188A1 (it) | 2016-06-08 | 2017-12-08 | Sofar Spa | Nuovo uso medico di probiotici |
| IT201600122724A1 (it) | 2016-12-02 | 2018-06-02 | Sofar Spa | Exopolysaccharides and uses thereof |
| IT201600127498A1 (it) | 2016-12-16 | 2018-06-16 | Sofar Spa | Probiotici per uso nella diverticolosi e malattia diverticolare |
| IT201600131819A1 (it) * | 2016-12-28 | 2018-06-28 | Metis Healthcare S R L | Preparazione per spray orale |
| IT201700101704A1 (it) * | 2017-09-12 | 2019-03-12 | Sofar Spa | Nuovo uso per trattamento delle infezioni da clostridium difficile |
| ES3049515T3 (en) * | 2017-12-06 | 2025-12-17 | Lac2Biome S R L | Composition based on probiotics and uses thereof |
| CN111973636A (zh) * | 2019-05-21 | 2020-11-24 | 王飞 | 一种肛肠凝胶及其制备方法 |
| DK3979982T3 (da) * | 2019-06-05 | 2023-07-03 | Lac2Biome S R L | Sammensætninger, der omfatter en bakteriestamme lactobacillus paracasei og hyaluronsyre, og anvendelse deraf til hudbehandling |
| IT201900008409A1 (it) * | 2019-06-07 | 2020-12-07 | Vivatis Pharma Gmbh | Individuazione e selezione di un materiale di partenza vegetale di condroitina solfato e acido ialuronico vegetali, e trasformazione di tale materiale di partenza vegetale per l’ottenimento di ingredienti per utilizzo in alimenti, integratori, dispositivi medici o farmaci |
| US11751597B2 (en) | 2019-11-05 | 2023-09-12 | Alfasigma S.P.A. | Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems |
| CN115551524A (zh) * | 2020-03-31 | 2022-12-30 | 赛瓦图斯有限公司 | 用于炎性肠病的组合疗法 |
| JP7718672B2 (ja) * | 2020-12-25 | 2025-08-05 | 日清食品株式会社 | 腸溶コーティング錠 |
| KR102752058B1 (ko) | 2023-08-25 | 2025-01-13 | 전남대학교 산학협력단 | 락토바실러스 루터리 nchbl-005 균주, 사균체 또는 이의 혼합물을 유효 성분으로 포함하는 염증성 질환 예방, 치료 또는 개선용 조성물 |
| IT202300027471A1 (it) * | 2023-12-20 | 2025-06-20 | Beingpharma S R L | Composizioni cosmetiche e collutori che le contengono per il benessere del cavo orale e dei denti |
| IT202300027477A1 (it) * | 2023-12-20 | 2025-06-20 | Beingpharma S R L | Composizioni e collutori che le contengono per il trattamento di disturbi e patologie del cavo orale |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0517363A (ja) * | 1991-07-11 | 1993-01-26 | Yakult Honsha Co Ltd | 抗炎症剤及びそれを含有する化粧料 |
| US5531989A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
| CN1066926C (zh) | 1996-04-08 | 2001-06-13 | 钟春燕 | 将椰子水发酵制作的食用纤维及其生产方法 |
| US6461607B1 (en) | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
| CZ9900769A3 (cs) | 1999-03-04 | 2000-10-11 | Petr Ing. Drsc. Hušek | Použití špičky s filtrem k vytvoření sloupce sorbentu s definovaným objemem v prostoru pod filtrem |
| US20020090416A1 (en) | 1999-03-09 | 2002-07-11 | Philip Connolly | Method of enhancing absorption and utilization of protein |
| IT1307850B1 (it) | 1999-03-15 | 2001-11-19 | Italmed Di Galli Giovanna E Pa | Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio |
| EP1145643A1 (en) | 2000-04-10 | 2001-10-17 | Phillip Connolly | Improved milk protein concentrate |
| US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| RU2182008C1 (ru) * | 2000-10-20 | 2002-05-10 | Самойленко Игорь Иннокентьевич | Вводимая перорально, ректально или интравагинально композиция, содержащая живые бактерии |
| US20030092163A1 (en) | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
| FI20020078A7 (fi) | 2002-01-15 | 2003-07-16 | Danisco | Immuunijärjestelmän stimulointi polydextroosilla |
| US6881419B2 (en) | 2002-04-09 | 2005-04-19 | William E. Lovett | Vitamin formulation for enhancing bone strength |
| EP1539192A1 (en) * | 2002-04-24 | 2005-06-15 | Medicarb AB | Composition and kit for the treatment of inflammatory bowel diseases |
| DK1530642T3 (da) | 2002-08-06 | 2010-03-08 | Danisco | Brug af lactobacillus til fremstilling af exopolysaccharider i fødevarer og farmaceutiske sammensætninger |
| AU2002951270A0 (en) | 2002-09-06 | 2002-09-19 | Vri Biomedical Ltd | Probiotic Bacterium and Methods of Use |
| WO2005001109A2 (en) | 2003-05-06 | 2005-01-06 | Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health | Methods and compositions to detect microbes in fecal samples |
| US20100112088A1 (en) | 2003-08-29 | 2010-05-06 | Jay Pravda | Materials and methods for treatment of disorders associated with oxidative stress |
| WO2005083122A2 (en) | 2004-02-27 | 2005-09-09 | Stichting Laboratorium Voor Infectieziekten | Method for detecting a microorganism in a fecal specimen |
| EP2514427A1 (en) * | 2004-03-04 | 2012-10-24 | E-L Management Corp. | Skin treatment method with lactobacillus extract |
| EP1815016B1 (en) | 2004-11-01 | 2012-06-27 | George Mason University | Compositions and methods for diagnosing colon disorders |
| CN101175416A (zh) | 2005-04-06 | 2008-05-07 | 诺瓦提斯公司 | 从营养方面改善葡萄糖控制和胰岛素作用的方法和组合物 |
| FI20051319L (fi) | 2005-12-22 | 2007-06-23 | Cyflo Oy | Menetelmä eläimen ja/tai ihmisen ravitsemuksen ja hyvinvoinnin ja eläinten tuottavuuden seuraamiseksi ja kehittämiseksi |
| CN1840206A (zh) | 2006-01-19 | 2006-10-04 | 上海交通大学 | 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法 |
| ES2426038T3 (es) | 2006-02-21 | 2013-10-18 | National University Corporation University Of Toyama | Procedimiento rápido para identificar el microorganismo causante de una enfermedad infecciosa |
| WO2007099830A1 (ja) * | 2006-02-24 | 2007-09-07 | Q.P. Corporation | 新規な低分子ヒアルロン酸および/またはその塩、ならびにこれを用いた化粧料、医薬組成物および食品組成物 |
| US20100166721A1 (en) | 2006-06-09 | 2010-07-01 | Fabiola Masri | Probotic compositions and uses thereof |
| US20080069861A1 (en) | 2006-09-19 | 2008-03-20 | National Starch And Chemical Investment Holding Corporation | Probiotic/Non-Probiotic Combinations |
| US20080081035A1 (en) | 2006-10-03 | 2008-04-03 | National Enzyme Company | Therapeutic protease compositions |
| JP5285617B2 (ja) | 2006-12-18 | 2013-09-11 | アドバンスド バイオニュートリション コーポレーション | 生きたプロバイオティクスを含む乾燥食物製品 |
| EP1972208A1 (en) | 2007-03-16 | 2008-09-24 | Kirin Holdings Kabushiki Kaisha | Composition for improving intestinal microflora |
| RU2009133376A (ru) | 2007-03-27 | 2011-05-10 | Дзе Проктер Энд Гэмбл Компани (US) | Способы и наборы для введения пробиотиков |
| US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| EP2173196B1 (en) | 2007-07-06 | 2011-02-16 | N.V. Nutricia | Use of probiotics and fibers for diarrhoea |
| US8193155B2 (en) * | 2009-02-09 | 2012-06-05 | Elc Management, Llc | Method and compositions for treating skin |
| US20090098088A1 (en) | 2007-10-10 | 2009-04-16 | The Procter & Gamble Company | Methods And Kits For The Treatment Of Diverticular Conditions |
| CN101240315A (zh) | 2008-02-21 | 2008-08-13 | 上海交通大学 | 检测药物防癌效果的非损伤性分子方法 |
| CA2721981A1 (en) | 2008-05-01 | 2009-11-05 | The Procter & Gamble Company | Methods and kits for the treatment of inflammatory bowel disorder conditions |
| WO2010008272A1 (en) * | 2008-07-15 | 2010-01-21 | N.V. Nutricia | Treatment of gut motility disorders |
| JP2010161944A (ja) | 2009-01-13 | 2010-07-29 | Syngen Biotech Co Ltd | 新型カゼイ菌の亜種(sg96)及びこれを含有する菌抑制組成物及びその用途 |
| ES2778836T3 (es) | 2009-03-05 | 2020-08-12 | Probiotical Spa | Cepas de bacterias que tienen una alta actividad antiinflamatoria |
| WO2010103132A1 (es) | 2009-03-10 | 2010-09-16 | Hero España, S.A. | Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna |
| ES2660008T3 (es) | 2009-09-23 | 2018-03-20 | Thomas Julius Borody | Terapia para infecciones entéricas crónicas |
| DK2498626T3 (en) | 2009-11-12 | 2015-07-13 | Nestec Sa | FOOD COMPOSITION TO PROMOTE GAS MICROFLORAL BALANCE AND HEALTH |
| RU2580040C2 (ru) | 2009-12-22 | 2016-04-10 | Проби Аб | Неферментированные композиции, включающие фракцию на основе злаков и пробиотик, и их применение |
| US8575130B2 (en) * | 2010-01-04 | 2013-11-05 | Holy Stone Healthcare Co., Ltd. | Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease |
| ITUD20100112A1 (it) * | 2010-06-09 | 2011-12-10 | Farma Derma S R L | Preparazione per uso vaginale e rettale e relativo procedimento di produzione |
| US11235008B2 (en) | 2011-03-31 | 2022-02-01 | Ganeden Biotech, Inc. | Probiotic sports nutrition compositions |
| WO2012154738A1 (en) * | 2011-05-09 | 2012-11-15 | The Cleveland Clinic Foundation | Composition and method to improve intestinal health |
| GB201219873D0 (en) | 2012-11-05 | 2012-12-19 | Multigerm Uk Entpr Ltd | Diverticulitis treatment |
| CN102919922A (zh) | 2012-11-08 | 2013-02-13 | 黑龙江省轻工科学研究院 | 一种复合益生菌发酵蓝莓果汁粉的制备方法 |
| KR20150134356A (ko) | 2013-03-05 | 2015-12-01 | 리엑스유니버시테이트 그로닝겐 | 염증을 억제하기 위한 페칼리 박테리움 프라우스니치이 htf-f (dsm 26943)의 용도 |
| JP6643984B2 (ja) | 2013-07-02 | 2020-02-12 | オーストリアノヴァ シンガポール プライベート リミテッド | カプセル化細胞を凍結乾燥する方法、凍結乾燥されたカプセル化細胞、凍結乾燥されたカプセル化細胞を含む組成物、ならびに、そのような細胞および組成物の使用 |
| ITMI20131473A1 (it) | 2013-09-06 | 2015-03-07 | Sofar Spa | Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale |
| ITMI20131467A1 (it) | 2013-09-06 | 2015-03-07 | Sofar Spa | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
| MA39710A (fr) * | 2014-04-23 | 2015-10-29 | Sofar Spa | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
| WO2015172191A1 (en) | 2014-05-12 | 2015-11-19 | Medlab Ip Pty Ltd | Probiotic compositions and uses thereof for treatment of obesity-related disorders |
| EP2990045B1 (en) | 2014-08-26 | 2016-11-16 | Chr. Hansen A/S | Bifidobacterium animalis subsp. lactis for use in decreasing abdominal pain in a postmenopausal woman |
| IT201600083376A1 (it) | 2016-08-08 | 2018-02-08 | Sofar Spa | Uso di probiotici per aumentare l’assorbimento proteico |
| WO2017195182A1 (en) | 2016-05-13 | 2017-11-16 | Sofar S.P.A. | Use of probiotics for improving protein absorption |
| ITUA20164188A1 (it) | 2016-06-08 | 2017-12-08 | Sofar Spa | Nuovo uso medico di probiotici |
| IT201600122724A1 (it) | 2016-12-02 | 2018-06-02 | Sofar Spa | Exopolysaccharides and uses thereof |
| US11207358B2 (en) | 2016-12-16 | 2021-12-28 | Compagnie Gervais Danone | Probiotic composition comprising Lactobacillus rhamnosus and Lactobacillus paracasei and methods thereof |
| IT201600127498A1 (it) | 2016-12-16 | 2018-06-16 | Sofar Spa | Probiotici per uso nella diverticolosi e malattia diverticolare |
| WO2019019961A1 (zh) | 2017-07-26 | 2019-01-31 | 海思科医药集团股份有限公司 | 防治消化道和/或皮肤反应的菌群及其应用 |
| IT201700101704A1 (it) | 2017-09-12 | 2019-03-12 | Sofar Spa | Nuovo uso per trattamento delle infezioni da clostridium difficile |
| ES3049515T3 (en) | 2017-12-06 | 2025-12-17 | Lac2Biome S R L | Composition based on probiotics and uses thereof |
| CN108743851A (zh) | 2018-08-09 | 2018-11-06 | 深圳市博奥生物科技有限公司 | 一种复合益生菌粉的制备方法及复合益生菌粉 |
| IT201900016811A1 (it) | 2019-09-20 | 2021-03-20 | Sofar Spa | Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali |
| IT201900016805A1 (it) | 2019-09-20 | 2021-03-20 | Sofar Spa | Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali |
| IT201900016865A1 (it) | 2019-09-20 | 2021-03-20 | Sofar Spa | Composizioni a base di ceppi batterici e loro uso come antinfiammatori |
| IT201900016850A1 (it) | 2019-09-20 | 2021-03-20 | Sofar Spa | Composizioni a base di ceppi batterici e estratti di bacche e loro uso come antinfiammatori |
| US11751597B2 (en) | 2019-11-05 | 2023-09-12 | Alfasigma S.P.A. | Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems |
| IT201900020422A1 (it) | 2019-11-05 | 2021-05-05 | Sofar Spa | Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine |
-
2015
- 2015-04-21 MA MA039710A patent/MA39710A/fr unknown
- 2015-04-22 US US15/305,470 patent/US11464814B2/en active Active
- 2015-04-22 EP EP15726329.4A patent/EP3134072A1/en not_active Withdrawn
- 2015-04-22 CA CA2944118A patent/CA2944118C/en active Active
- 2015-04-22 WO PCT/IB2015/052938 patent/WO2015162570A1/en not_active Ceased
- 2015-04-22 JP JP2016564193A patent/JP2017513906A/ja active Pending
-
2022
- 2022-10-06 US US17/961,478 patent/US20230052820A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2944118C (en) | Topical composition for use in the treatment of inflammatory bowel disease | |
| Hoesl et al. | The probiotic approach: an alternative treatment option in urology | |
| RU2017127597A (ru) | Применение короткоцепочечных жирных кислот для профилактики рака | |
| Mego et al. | Probiotic bacteria in cancer patients undergoing chemotherapy and radiation therapy | |
| HRP20180053T1 (hr) | Novi soj bakterije bifidobacterium animalis subsp. lactis cect 8145 i njegova upotreba u liječenju i/ili sprječavanju prekomjerne težine i pretilosti, te bolesti povezanih s njima | |
| JP2018504457A5 (cg-RX-API-DMAC10.html) | ||
| EP3554522B1 (en) | Probiotics for use in the treatment of diverticulosis and diverticular disease | |
| RU2011150216A (ru) | Детские питательные смеси, содержащие пробиотические микроорганизмы | |
| JP2008520640A5 (cg-RX-API-DMAC10.html) | ||
| RU2007106038A (ru) | Композиция на основе пробиотических бактерий и ее применение в профилактике и/или лечении респираторных патологий и/или инфекций и в улучшении функции кишечника | |
| JP2013507394A5 (cg-RX-API-DMAC10.html) | ||
| JP2010528093A5 (cg-RX-API-DMAC10.html) | ||
| RU2009121623A (ru) | Композиция для введения биологически активных веществ во влагалище и прямую кишку и ее применения | |
| RU2019116519A (ru) | Композиция для направленной доставки биологически активного компонента в толстую кишку и ее применение | |
| RU2013126609A (ru) | Экструдированные нереплицирующиеся пробиотические микроорганизмы и их польза для здоровья | |
| RU2018139655A (ru) | Бифидобактерии для увеличения безжировой массы тела | |
| JP2008500294A5 (cg-RX-API-DMAC10.html) | ||
| Kumari et al. | Clinical importance of lactic acid bacteria: a short review | |
| RU2013126604A (ru) | Нереплицирующиеся пробиотические бактерии и профилактика или терапия инфекций с тем, чтобы уменьшить пропуски посещений школы или учреждений дневного ухода за детьми | |
| RU2013126602A (ru) | Нереплицирующиеся пробиотические микроорганизмы, защищающие детей против желудочно-кишечных инфекций | |
| JP2020505361A5 (cg-RX-API-DMAC10.html) | ||
| Setijawati et al. | The Effect of Lactobacillus acidophilus microcapsule which encapsulated by kappa caragenan toward in vivo functional test | |
| RU2007104090A (ru) | БАКТЕРИАЛЬНЫЕ ШТАММЫ Bifidobacterium, ПРОДУЦИРУЮЩИЕ ФОЛИЕВУЮ КИСЛОТУ, ПРЕПАРАТЫ И ИХ ПРИМЕНЕНИЕ | |
| Shahrampour et al. | Films and coatings containing probiotic microorganisms: A new approach for production of probiotic products | |
| FAZELI et al. | Cytotoxic activity of familact: A probiotic supplement |